EMA Authorised: Stalevo (levodopa;carbidopa;entacapone) — Orion Corporation

View source ↗

Summary

The EMA has authorised Stalevo, a fixed-dose combination of levodopa, carbidopa and entacapone, for Parkinson's disease, with Orion Corporation as the marketing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Stalevo (levodopa;carbidopa;entacapone)

Snippet

Status: Authorised. Therapeutic area: Parkinson Disease. MAH: Orion Corporation. Decision date: 12/12/2024